docosenoic acid | 20831-69-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: docosenoic acid
• 英文别名: docos-2t-enoic acid；Docos-2t-ensaeure；docosamonoenoic acid；(E)-docos-2-enoic acid
• CAS: 20831-69-0
• 化学式: C₂₂H₄₂O₂
• 分子量: 338.574
• InChiKey: ATNNLHXCRAAGJS-QZQOTICOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.3
• 重原子数：
  24
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  docosenoic acid 生成 trans-2-docosenoic acid methyl ester
  参考文献：
  名称：

  ROHWEDDER, WILLIAM K.;DUVAL, SANDRA M.;WOLF, DARHAL J.;EMKEN, EDWARD A., LIPIDS., 25,(1990) N, C. 401-405

  摘要：

  DOI：
• 作为产物：
  描述：

  二十二酸 在 溴 作用下， 生成 docosenoic acid
  参考文献：
  名称：

  Kannan,R. et al., Indian Journal of Chemistry, 1971, vol. 9, p. 730 - 731

  摘要：

  DOI：

文献信息

• Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids
  作者：Anne Loesche、Jana Wiemann、Zayan Al Halabi、Julia Karasch、Wolfgang Sippl、René Csuk

  DOI：10.1016/j.bmcl.2018.09.013

  日期：2018.11

  A small library of (E) α,β-unsaturated fatty acids was prepared, and 20 different saturated and mono-unsaturated fatty acids differing in chain length were subjected to Ellman’s assays to determine their ability to act as inhibitors for AChE or BChE. While the compounds were only very weak inhibitors of BChE, seven molecules were inhibitors of AChE holding IC50 = 4.3–12.8 M with three of them as significant

  制备了一个小的（E）α，β-不饱和脂肪酸文库，并对20种链长不同的饱和和单不饱和脂肪酸进行了Ellman分析，以确定它们充当AChE或BChE抑制剂的能力。虽然这些化合物只是BChE的非常弱的抑制剂，但有7个分子是AChE的抑制剂，IC 50  = 4.3-12.8 M，其中三个是该酶的重要抑制剂。结果表明，反式2-单不饱和脂肪酸比其饱和类似物是更好的AChE抑制剂。此外，筛选结果表明链长对于获得抑制功效至关重要。对于（2 E）二十碳烯酸（图14）显示了抑制常数K i  = 1.51±0.09 M和K i '= 7.15±0.55M。所有测试的化合物均为竞争性主要成分的混合型抑制剂。分子模型计算表明活性/非活性化合物与酶AChE和BChE的结合方式不同。
• Novel Process for the Synthesis of Docosanol
  申请人：Biophore India Pharmaceuticals PVT. Ltd.

  公开号：US20190161425A1

  公开（公告）日：2019-05-30

  The present invention relates to a novel process for the preparation of Docosanol (I). More particularly, the invention relates to a novel process for the preparation of Docosanol (I) in a substantially pure form with a purity level of greater than 99.5%. The invention also relates to novel crystalline forms of Docosanol (I) and process for preparation thereof.

  本发明涉及一种用于制备十二烷醇（I）的新型工艺。更具体地说，该发明涉及一种用于以高于99.5%纯度水平制备十二烷醇（I）的新型工艺。该发明还涉及十二烷醇（I）的新型晶型形式及其制备工艺。
• Oil/fat composition
  申请人：Kao Corporation

  公开号：EP1430783A1

  公开（公告）日：2004-06-23

  Provided is an oil/fat composition comprising 10.1 to 94.9 wt.% of a triglyceride, 0.1 to 30 wt.% of a monoglyceride and 5 to 59.9 wt.% of a diglyceride which has, as a fatty acid constituent thereof, 15 to 90 wt.% of an ω 3-unsaturated fatty acid having less than 20 carbon atoms. The oil/fat composition of the present invention has excellent heat stability, has body-fat-accumulation resisting action, visceral-fat-accumulation resisting action, blood-sugar-level lowering action, insulin resistance improving action and leptin lowering action and is useful for, as well as pharmaceuticals, preventive or remedial food for diabetes or obesity, and feed.

  本发明提供了一种油/脂组合物，它包含 10.1 至 94.9 重量百分比的甘油三酯、0.1 至 30 重量百分比的单甘油酯和 5 至 59.9 重量百分比的二甘油酯，其脂肪酸成分为 15 至 90 重量百分比的碳原子数少于 20 的ω 3-不饱和脂肪酸。 本发明的油脂组合物具有良好的热稳定性，具有抗体脂积累作用、抗内脏脂肪积累作用、降低血糖水平作用、改善胰岛素抵抗作用和降低瘦素作用，可用于制药、糖尿病或肥胖症的预防或治疗食品以及饲料。
• DRUG FOR REDUCING SIDE EFFECTS IN RIBAVIRIN INTERFERON COMBINATION THERAPY
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1595539A1

  公开（公告）日：2005-11-16

  There is provided a drug for reducing side effects, anemia in particular, in combination therapy of chronic hepatitis C with ribavirin and interferon, which contains as the active ingredient at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof.

  本发明提供了一种药物，用于在利巴韦林和干扰素联合治疗慢性丙型肝炎时减少副作用，尤其是贫血，该药物含有至少一种选自二十碳五烯酸（EPA）及其药学上可接受的盐类和酯类的活性成分。
• COMPOSITION FOR PREVENTION/TREATMENT FOR VARICOSE VEINS
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1637134A1

  公开（公告）日：2006-03-22

  A preventive/therapeutic agent for varicose veins or a composition for the prevention or alleviation of symptoms relevant to varicose veins. The preventive/therapeutic agent for varicose veins or the composition for the prevention or alleviation of symptoms relevant to varicose veins each is characterized by containing eicosapentaenoic acid.

  一种静脉曲张预防/治疗剂或一种用于预防或缓解静脉曲张相关症状的组合物。静脉曲张预防/治疗剂或用于预防或缓解静脉曲张相关症状的组合物的特征是含有二十碳五烯酸。